Novavax (NVAX) delivered earnings and revenue surprises of 312.68% and 215.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 71 cents per share. The vaccine maker posted revenue of $666.7 million in the period, also beating ...

D-Wave Quantum Inc. QBTS, Asset Entities, Inc. ASST, Alphabet, Inc. GOOG GOOGL, Novavax, Inc. NVAX and Carvana Co. CVNA are ...

Shares of Novavax, Inc. (NVAX) traded 16% higher on Thursday morning after the company reported upbeat first-quarter (Q1) ...

Analysts are estimating that Novavax will report an earnings per share (EPS) of $0.19. The market awaits Novavax's ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

We expect Novavax NVAX to surpass expectations when it reports first-quarter 2025 earnings on May 8, before the opening bell.

Novavax (NASDAQ:NVAX) has updated the terms of the previously announced collaboration and licensing agreement with Takeda (TAK).